Department of Neurology and Clinical Neurosciences, Stanford University, Palo Alto, CA, USA.
Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
J Neuromuscul Dis. 2023;10(2):199-209. doi: 10.3233/JND-221573.
Novel Spinal Muscular Atrophy (SMA) treatments have demonstrated improvements on motor measures that are clearly distinct from the natural history of progressive decline. Comparable measures are needed to monitor bulbar function, which is affected in severe SMA.
To assess bulbar function with patient-reported outcome measures (PROs) and determine their relationships with clinical characteristics.
We recruited 47 non-ambulatory participants (mean (SD) age = 29.8 (13.7) years, range = 10.3-73.2) with SMA. PROs including Voice Handicap Index (VHI) and Eating Assessment Tool-10 (EAT-10) were collected alongside clinical characteristics and standardized motor assessments. Associations were assessed using Spearman correlation coefficients and group comparisons were performed using Wilcoxon rank sum tests.
A majority of the 47 participants were SMA type 2 (70.2%), non-sitters (78.7%), 3 copies of SMN2 (77.5%), and using respiratory support (66.0%). A majority (94%) reported voice issues primarily in 8/30 VHI questions. Problems included: difficulty understanding me in a noisy room (87.2%); difficult for people to hear me (74.5%); and people ask me to repeat when speaking face-to-face (72.3%). A majority (85.1%) reported swallowing issues primarily in 3/10 EAT-10 questions: swallowing pills (68.1%); food sticks to my throat (66.0%); and swallowing solids (61.7%). The two PROs were moderately associated (rs = 0.66).
Weaker individuals with SMA experience bulbar problems including difficulties with voice and swallowing. Further refinement and assessment of functional bulbar scales will help determine their relevance and responsiveness to changes in SMA. Additional study is needed to quantify bulbar changes caused by SMA and their response to disease-modifying treatments.
新型脊髓性肌萎缩症(SMA)治疗方法已证明在运动指标上的改善明显不同于疾病进行性下降的自然史。需要类似的措施来监测严重 SMA 患者的球部功能。
使用患者报告的结局测量(PROs)评估球部功能,并确定其与临床特征的关系。
我们招募了 47 名非运动性参与者(平均(SD)年龄 29.8(13.7)岁,范围 10.3-73.2),患有 SMA。PROs 包括语音障碍指数(VHI)和饮食评估工具-10(EAT-10),与临床特征和标准化运动评估一起收集。使用 Spearman 相关系数评估相关性,并使用 Wilcoxon 秩和检验进行组间比较。
47 名参与者中大多数为 SMA 2 型(70.2%)、非坐位(78.7%)、SMN2 3 个拷贝(77.5%)和使用呼吸支持(66.0%)。大多数(94%)报告主要在 8/30 VHI 问题中存在语音问题。问题包括:在嘈杂的房间里难以理解我(87.2%);人们很难听到我(74.5%);面对面说话时人们要求我重复(72.3%)。大多数(85.1%)报告吞咽问题主要在 3/10 EAT-10 问题中存在:吞咽药丸(68.1%);食物卡在喉咙里(66.0%);吞咽固体(61.7%)。两个 PROs 中度相关(rs=0.66)。
较弱的 SMA 患者会经历球部问题,包括语音和吞咽困难。进一步细化和评估功能性球部量表将有助于确定其在 SMA 中的相关性和对疾病的反应性。需要进一步研究来量化 SMA 引起的球部变化及其对疾病修饰治疗的反应。